BOLD Boundless Bio, Inc.
Mergers ·
Boundless Bio filed a Form S-4 on October 8, 2026 for its merger with private Serapha Bio. The filing estimates about 8.6737 Boundless shares for each Serapha share before a planned reverse split, and expects existing Boundless holders to own about 3.8% of the combined company.
Boundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai.
Boundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028.
Boundless Bio filed a Form S-3 on April 1, 2025 covering up to $400.0 million of securities. The same day it signed an at-the-market sales agreement with Jefferies LLC for up to $14.5 million of common stock, which can start only after the SEC declares the registration effective.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $44.8 million | $55.3 million |
| Net income (loss) | -$58.2 million | -$65.4 million |
| Cash from operations | -$46.7 million | -$60.8 million |
| Cash and equivalents | $17.9 million | $26.6 million |
| Short-term investments | $89.7 million | $125.5 million |
Our latest story on this, dated Oct 8, 2026: "Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 1, 2025: "Boundless Bio files $400.0 million shelf and $14.5 million Jefferies stock program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 8, 2026: "Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data". The story links the filing or release it is based on. Read the story.
Boundless Bio, Inc. trades under the ticker BOLD on NASDAQ.
Boundless Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Boundless Bio, Inc. is 1782303. Its filings are on SEC EDGAR.
22,747,985 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Boundless Bio, Inc. under United States.
Our directory classifies Boundless Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Boundless Bio, Inc. is US10170A1007.
aibio.space lists Boundless Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Boundless Bio, Inc. reported a net loss of $58.2 million for the fiscal year ended Dec 31, 2025, and used $46.7 million of cash in operations, per its annual report to the SEC.
$44.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$72.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Filed documents for a merger or acquisition. SEC Form S-4. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,3.02,5.01,5.02,7.01,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.03). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01). Source
Reported a financing. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio